Welcome to our dedicated page for Qiagen news (Ticker: QGEN), a resource for investors and traders seeking the latest updates and insights on Qiagen stock.
Qiagen N.V. (QGEN) delivers essential molecular testing solutions powering advancements in healthcare, research, and applied sciences. This dedicated news hub provides investors and professionals with authoritative updates on Qiagen's innovations in sample preparation, automated diagnostics, and bioinformatics.
Access real-time announcements including earnings reports, regulatory milestones, and strategic partnerships. Our curated collection features press releases on product launches, clinical study collaborations, and technology integrations across molecular diagnostics and life sciences.
Key updates cover Qiagen's expanding portfolio for precision medicine, infectious disease testing, and next-generation sequencing workflows. Track developments in critical areas like companion diagnostics and laboratory automation solutions serving global healthcare providers and research institutions.
Bookmark this page for streamlined access to Qiagen's official communications. Stay informed about the company's progress in transforming biological insights into actionable results across 40+ countries.
QIAGEN and OncXerna Therapeutics have entered into a master companion diagnostics agreement to develop a next-generation sequencing (NGS) companion diagnostic for OncXerna’s candidate Navicixizumab, aimed at treating ovarian cancer. The agreement includes a non-exclusive license for the Xerna™ TME panel, which uses RNA-based gene expression data to identify suitable patients. The collaboration aims to advance the Xerna™ TME panel towards regulatory approval, enhancing QIAGEN's position in precision medicine diagnostics and potentially benefiting ovarian cancer patients.
QIAGEN (NYSE: QGEN) has received emergency use authorization from the FDA for its QIAreach® SARS-CoV-2 Antigen Test. This rapid test detects active SARS-CoV-2 infections within 2 to 15 minutes and processes approximately 30 samples per hour, boasting a sensitivity of at least 80% and a specificity of 98%. The test is designed for high-volume testing environments, allowing for simultaneous tests of active and past infections with the QIAreach Anti-SARS-CoV-2 Total Test. This innovation is part of QIAGEN's commitment to enhance COVID-19 testing capabilities.
QIAGEN N.V. (NYSE: QGEN) reported strong financial results for Q2 and the first half of 2021, with a 28% increase in net sales to $567.3 million in Q2. Sales for H1 2021 rose 39% to $1.135 billion. Diluted EPS for Q2 was $0.52, up 22% year-over-year, while adjusted EPS reached $0.67. The company noted reduced demand for COVID-19 testing due to rising vaccination rates but remains optimistic about growth in non-COVID product groups and plans a $100 million share repurchase program.
QIAGEN N.V. (NYSE: QGEN) announced preliminary Q2 2021 results and updated its full-year outlook. A conference call is set for July 13, 2021, at 15:00 CET / 9:00 EDT, hosted by CEO Thierry Bernard and CFO Roland Sackers. Stakeholders can join by dialing +1 929 477 0402 (U.S.) or other regional numbers. The company continues to provide Sample to Insight solutions for over 500,000 customers globally across molecular diagnostics and life sciences sectors.
QIAGEN N.V. (NYSE: QGEN) announced strong preliminary results for Q2 2021, with net sales up 28% to $567.3 million, exceeding the expected 20% growth. Adjusted EPS rose about 21% to $0.66-0.67, surpassing projections. Non-COVID product sales surged 52% to $407.6 million, making up 72% of total sales, while COVID-19 product sales declined 17% to $159.7 million due to increased vaccination rates. The company revealed plans for a $100 million share repurchase program to enhance shareholder value, reflecting confidence in future growth.
QIAGEN N.V. (NYSE: QGEN) has announced CE-IVD certification for its NeuMoDx™ HAdV Quant Assay, which identifies and quantifies human adenovirus DNA. This assay is the 15th addition to the NeuMoDx 96 and 288 Molecular Systems, enabling critical testing for immunocompromised patients. Developed with Sentinel Diagnostics, the assay enhances QIAGEN's offerings in transplant health by complementing existing tests for CMV, EBV, and BKV. The NeuMoDx systems provide a comprehensive portfolio, supporting various viral and bacterial pathogen testing.
QIAGEN N.V. (NYSE: QGEN) has launched the Workflow Configurator, a cloud-based tool designed to help life sciences researchers optimize their experiments. This application allows users to select applications, biological materials, and analytes, quickly identifying suitable products from QIAGEN's extensive portfolio. The configurator enhances efficiency by integrating with My QIAGEN and QIAGEN's Web Shop, enabling seamless workflow management. This launch is part of QIAGEN's strategy to digitalize its offerings, emphasizing the importance of digital tools in the life sciences industry.
QIAGEN (NYSE:QGEN) has entered a strategic alliance with Japan’s Sysmex Corporation to enhance cancer companion diagnostics leveraging QIAGEN’s expertise and Sysmex’s Plasma-Safe-SeqS technology. The partnership focuses on collaborating with pharmaceutical companies to develop drug treatments and promote liquid biopsy diagnostics. QIAGEN, a pioneer in precision medicine, boasts an extensive portfolio of FDA-approved diagnostic products and holds master collaboration agreements with over 25 companies. This alliance aims to improve clinical decision-making and patient outcomes in cancer treatment globally.
QIAGEN N.V. (NYSE: QGEN) has formed a strategic partnership with Verogen Inc. to enhance next-generation sequencing (NGS) tools for human identification workflows. This agreement grants QIAGEN global distribution rights for Verogen's products and involves collaboration on forensically validated NGS workflows. The partnership aims to provide laboratories with comprehensive solutions, optimizing QIAGEN’s sample prep automation alongside Verogen’s innovative NGS capabilities. This collaboration is expected to drive the adoption of NGS technology in forensic applications, improving insights from casework samples.
QIAGEN N.V. (NYSE: QGEN) announced a partnership with Verogen, enhancing its offerings in human identification workflows. This collaboration allows QIAGEN to distribute Verogen's sequencing solutions, including the ForenSeq assay and MiSeq FGx sequencing system, globally. Both companies will develop forensically validated workflows that combine their products and expertise. This partnership aims to accelerate the adoption of next-generation sequencing (NGS) in forensics, providing laboratories with improved tools for human identification. Financial terms were not disclosed.
